• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
The State of the Phase I Market Product Image

The State of the Phase I Market

  • ID: 2100852
  • July 2011
  • 113 Pages
  • Industry Standard Research (ISR)

FEATURED COMPANIES

  • CEDRA
  • Charles River
  • i3 Pharma Services
  • INC Research
  • Medpace
  • PharmaNet
  • MORE

Market size, growth estimates, and service quality and loyalty profiles for major Phase I service providers

- Which Phase I service providers best meet sponsors’ service quality expectations?
- Are Phase I studies becoming more global?
- How much work is being outsourced to Large, Mid-size, and Specialized Phase I providers?
- Are sponsors outsourcing closer to home?
- What proportion of Phase I studies include patients?
- What can I expect the market to look like in 2014?

Those questions and more are answered within “The State of the Phase I Market” report, which has been compiled through primary research of over 100 pharmaceutical decision makers with Phase I responsibilities.
Report Content:

This report is divided into four sections:

1. Market Dynamics: Including the volume of Phase I studies and the volume of Phase I studies being outsourced, market size estimates for Phase I services and proportion of work that will be distributed amongst large global, mid-size multi-service, and specialty Phase I CROs, and how, if at all, sponsors see patient populations, multi-center studies, and other trends influencing study conduct READ MORE >

FEATURED COMPANIES

  • CEDRA
  • Charles River
  • i3 Pharma Services
  • INC Research
  • Medpace
  • PharmaNet
  • MORE

The State of the Phase I Market

Copyright and Usage Guidelines

Methodology

Study Findings

Market Dynamics

Evolving Study Characteristics

Growth and Decline in Study Volume and Outsourcing

Outsourcing over the past few years

Recent and Future Outsourcing Volume
Current Outsourcing by Service Provider Type

Outsourcing by Service Provider Type – in 3 Years

Phase I Study Market Size Estimate - For the top 100 Biopharma Companies

Geographic Implications

Current and Future Regional Study Conduct

Service Provider Selection

Leadership Perceptions

Industry Leaders

Proposal Requests by Company

Received Proposals

Service Provider Use (and use more)

Service Provider Usage

Future use of Service Providers
Provider Selection Criteria

Most Important Service Provider Attributes

Service Provider Preference

Preferred Phase I Service Provider

Service Quality

Appendix of Charts and Graphs

Respondent Demographics

Company Characteristics

Organization Type

Organization Size by R&D Spending

Respondent Job Title

Respondent and Company HQ Location

Functional Area Responsibility

Scope of Responsibility – In-house vs. Outsource

Service Provider Responsibility

Therapeutic Area Focus

Respondent Tenure

Drivers of decreased demand

Recent Outsourcing Volume

Phase I study volume

Drivers of future Phase I volume

Current proportion of studies in Patients vs. Healthy Volunteers

Future Current proportion of studies in Patients vs. Healthy Volunteers

In-house Units
Locations of in-house Phase I units

Current outsourcing for Clinical vs. Support services

Future outsourcing for Clinical vs. Support services

Drivers of Change

Proportion of spend to different service provider segments - Current

Proportion of spend to different service provider segments – In 3 Years

Number of Preferred Providers

Service Provider Delivery Quality

Averion

Bioclinica

Biomedical Systems

CEDRA

Cetero

Charles River

Chiltern

Clearstone

Clinsys

Covance

DCRI – Duke

Eurofins

i3 Pharma Services

ICON

INC Research

Kendle

Medpace

Omnicare

Paragon Biomedical

PAREXEL

PharmaNet

PPD

PRA

Premier Research

Quintiles

Radiant

SGS Life Sciences

Siro Clinpharm

US Oncology

West Coast Clinical Trials

World Wide Clinical Trials

Benefits of working with Large full service CROs

Benefits of working with Mid-size Multi-service CROs

Benefits of working with Dedicated Phase I providers

Regions of Phase I Execution

North America

Western Europe

Eastern Europe

Russia

IndiA
South America

Japan

China

Asia-Pacific

Other

Future Regions for Phase I Execution

North America

Western Europe

Eastern Europe

Russia

India

South America

Japan

China

Asia-Pacific

Other

Sole Source Arrangements for Phase I Services

Company’s Approach

Important Service Provider Attributes

Predictions for India in the Next 5 Years

Healthy Volunteers

Trends in Phase I Study Characteristics

Patient Use

Study Complexity

Multiple Sites/ Centers

Multiple Countries

Hospitals or Academic Centers

Recommendations for Focus

Service Provider Differentiation

- CEDRA
- Cetero
- Charles River
- Covance
- i3 Pharma Services
- ICON
- INC Research
- Kendle
- Medpace
- PAREXEL
- PharmaNet
- PPD
- PRA
- Quintiles
- SGS Life Sciences
- West Coast Clinical Trials

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos